Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation
Why the study?
It was unknown whether platelet reactivity on clopidogrel therapy measured by a point-of-care assay is associated with thrombotic events after PCI with drug-eluting stents.
Does high post-treatment platelet reactivity on clopidogrel increase the risk of thrombotic events in patients undergoing PCI with drug-eluting stents?
Population
380 patients undergoing PCI with sirolimus-eluting stents
Comparison
Post-treatment platelet reactivity greater than cut-off vs below cut-off
Follow-up
6 month
Authors
Discussion
Loading...
Member takes
Implication
May improve risk stratification after DES-PCI but should not change practice; leaves open whether testing-guided therapy improves outcomes.**[[1]](https://academic.oup.
Structured PICO
Does high post-treatment platelet reactivity on clopidogrel increase the risk of thrombotic events in patients undergoing PCI with drug-eluting stents?
P
Population
380 patients undergoing percutaneous coronary intervention (PCI) with sirolimus-eluting stents
I
Intervention
High post-treatment platelet reactivity on clopidogrel therapy (≥235 PRU measured by VerifyNow P2Y12 assay)
C
Comparator
Low post-treatment platelet reactivity on clopidogrel therapy (<235 PRU)
O
Outcome
Composite of 6-month out-of-hospital cardiovascular (CV) death, non-fatal MI, or stent thrombosiscomposite
High post-treatment platelet reactivity on clopidogrel, assessed by a point-of-care assay, is associated with an increased risk of ischemic events including stent thrombosis after PCI with drug-eluting stents.
Cite This Study
Price et al. (2008) studied this question.